364
Participants
Start Date
April 19, 2010
Primary Completion Date
November 23, 2017
Study Completion Date
November 26, 2017
Gemcitabine+Cisplatin
Gemcitabine d1,8, Cisplatin d1, 21 days as a course, up to 6 courses.
BIBW 2992
starting dose is 40 mg, in the event of no or minimal drug-related adverse events after one course, the dose will be increased to 50mg. in the event of certain drug related Adverse Event (AE), dose reduction will be increments of 10 mg, with the lowest dose being 20mg.
Songklanagarind Hospital, Songkhla
Beijing Chao-Yang Hospital, Beijing
307 Hospital of PLA, Beijing
Peking Union Medical College Hospital, Beijing
Beijing Chest Hospital, Beijing
The First Hospital of Chinese Medical University, Shenyang
First Hospital of Jilin University, Changchun
The Third Affiliated Hospital of Harbin Medical University, Haerbin
Shanghai Changzheng Hospital, Shanghai
Shanghai Chest Hospital, Shanghai
Zhongshan Hospital Fudan University, Shanghai
Shanghai Pulmonary Hospital, Shanghai
Changhai Hospital, Shanghai
the 81th Hospital of PLA, Nanjing
Jiangsu Cancer Hospital, Nanjing
Northern Jiangsu People's Hospital, Yangzhou
The affiliated hospital of medicalcollege qingdao university, Qingdao
Lin Yi Tumor Hospital, Linyi
Zhejiang Cancer Hospital, Hangzhou
Fujian Provincial Tumor Hospital, Fuzhou
Chungbuk National University Hospital, Cheongju-si
Xiangya Hospital, Central South University, Changsha
Guangdong General Hospital, Guangzhou
Guangzhou Institute of Respiratory Disease, Guangzhou
NanFang Hosptial, Guangzhou
West China Hospital, Chengdu
Yunnan Provincial Tumor Hospital, Kunming
Tangdu Hospital, Xi'an
Hunan Province Tumor Hospital, Changsha
Hubei Cancer Hospital, Hongshan
The Affiliated Cancer Hospital, Guangxi Medical University, Nanning
Hebei Provincial Tumor Hospital, Shijiazhuang
Kosin University Gospel Hospital, Busan
Yeungnam University Medical Center, Daegu
Konkuk University Medical Center, Seoul
Korea University Guro Hospital, Seoul
Lead Sponsor
Boehringer Ingelheim
INDUSTRY